Literature DB >> 18790615

Renal function as a predictor of linezolid-induced thrombocytopenia.

Kazuaki Matsumoto, Yasuo Takeda, Ayumi Takeshita, Naoko Fukunaga, Akari Shigemi, Keiko Yaji, Yoshihiro Shimodozono, Katsushi Yamada, Kazuro Ikawa, Norifumi Morikawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18790615     DOI： 10.1016/j.ijantimicag.2008.07.002

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  13 in total

Review 1.  Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature.

Authors:  A P Cossu; M Musu; P Mura; L M De Giudici; G Finco
Journal:  Eur J Clin Pharmacol       Date:  2014-01       Impact factor: 2.953

2.  Risk factors for thrombocytopenia in adult chinese patients receiving linezolid therapy.

Authors:  Chao Chen; Dai-Hong Guo; Xiutang Cao; Yun Cai; Yuanjie Xu; Man Zhu; Liang Ma
Journal:  Curr Ther Res Clin Exp       Date:  2012-12

3.  Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.

Authors:  Ryan L Crass; Pier Giorgio Cojutti; Manjunath P Pai; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.

Authors:  Yasuhiro Tsuji; Nicholas H G Holford; Hidefumi Kasai; Chika Ogami; Young-A Heo; Yoshitsugu Higashi; Akiko Mizoguchi; Hideto To; Yoshihiro Yamamoto
Journal:  Br J Clin Pharmacol       Date:  2017-03-31       Impact factor: 4.335

5.  Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients.

Authors:  Julien Cazavet; Fanny Vardon Bounes; Stéphanie Ruiz; Thierry Seguin; Laure Crognier; Antoine Rouget; Olivier Fourcade; Vincent Minville; Jean-Marie Conil; Bernard Georges
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-18       Impact factor: 3.267

6.  In Vitro Activity of Tedizolid against Mycobacterium tuberculosis.

Authors:  Pilar Ruiz; Manuel Causse; Manuel Vaquero; Manuel Casal
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

7.  Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients.

Authors:  H-Y Dong; J Xie; L-H Chen; T-T Wang; Y-R Zhao; Y-L Dong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-12       Impact factor: 3.267

8.  Predictive score of haematological toxicity in patients treated with linezolid.

Authors:  J González-Del Castillo; F J Candel; R Manzano-Lorenzo; L Arias; E J García-Lamberechts; F J Martín-Sánchez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-03-25       Impact factor: 3.267

9.  Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.

Authors:  Tomohiro Sasaki; Hiroshi Takane; Katsuhiro Ogawa; Sayaka Isagawa; Takeshi Hirota; Shun Higuchi; Toshinobu Horii; Kenji Otsubo; Ichiro Ieiri
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

10.  Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment.

Authors:  Ernane Souza; Ryan L Crass; Jeremy Felton; Kengo Hanaya; Manjunath P Pai
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.